Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
NCT00168922
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Small Cell Lung Cancer
Interventions
DRUG:
Bendamustin/Ribomustin
Sponsor
Charite University, Berlin, Germany
Collaborators
[object Object]